ヒトオルガノイド市場 – 2029年までの世界予測

Report Overview

The value of the human organoids market will increase from an estimated USD 1.19 billion in 2024 to USD 2.33 billion in 2029, at a CAGR of 14.4% through the forecast period.

ヒトオルガノイド市場の価値は、2024年の推定11億9,000万米ドルから2029年には23億3,000万米ドルに、予測期間を通じて14.4%のCAGRで増加すると予想されます。

Advancement in funding for research in human organoids directly promotes the growth of the market for organoids with significant improvement in research capabilities and increases the scope of applications. Financial support brings scientists to explore organoids in various fields, such as cancer, neurodegenerative diseases, and drug development, which attracts pharmaceutical and biotech companies. A more commercialized version of the organoid technologies along with a clear regulatory framework will even further ease access to the market. This, in turn, is fuelling the growth of the global human organoids market. Although the growing interest in human organoids provides a major market potential, there is a dearth of skilled labor. With such increasing demand in innovative organoid technology, the shortage of qualified personnel who are able to develop and use such complex models has become a challenge to the continued research and commercialization effort.

“Developmental biology segment is expected to have the fastest growth rate in the human organoids market, by application, during the forecast period.”

The human organoids market is segmented into developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, regenerative medicine, and other applications, based on application. Human organoids represent an essentially much more ethically compliant and efficient alternative to studying human-specific developmental biology and the processes leading to disease. It is therefore increasingly being applied, especially in academic and research centers specializing in developmental biology.

“Pharmaceutical & biotechnology companies segment accounted for the highest growth rate in the human organoids market, by end user, during the forecast period.”

Based on end user, the human organoids market is bifurcated into into pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users. The pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR in the market of human organoids mainly due to their intense research and development activities, where they use organoids in drug discovery, disease modeling, and personalized medicine. These companies employ organoids in developing new drugs and testing them for the efficacy and toxicity of the drug, besides gaining insights into the complexities of a diseaseat a cellular level.

“Asia Pacific: The fastest-growing region in human organoids market.”

The worldwide market for human organoids is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. Notably, the Asia-Pacific region marks the highest CAGR in the human organoids market, due to increasing investments into healthcare infrastructure and research that advance the capabilities of medical facilities. In addition to this, the number of rapidly aging patients strongly demands effective treatments for diseases related to age. Consequently, human organoids act as great models for the study of such conditions. The growing medical tourism activities in the APAC region also happen to be of great influence for the market, given the rapid increase of patients seeking advanced treatments and high-class healthcare services. These factors, collectively, have put the APAC region on a growth trajectory for human organoids markets.

The break-up of the profile of primary participants in the human organoids market:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in this market are Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), Kirkstall Ltd. (UK), MIMETAS BV (Netherlands), Neuromics (US), PRIMACYT Cell Culture Technology GmbH (Germany), STEMCELL Technologies (Canada), ACROBiosystems (China), Biopredic International (France), CN Bio Innovations Ltd. (UK), CYPRIO (France), Emulate, Inc. (US), Kerafast, Inc. (US), Pandorum Technologies Pvt. Ltd (India), CYFUSE BIOMEDICAL K.K. (Japan), NeyroblastGX LLC (US), 3Dnamics Inc. (US), and DefiniGEN Limited (UK).

Research Coverage:

This research report categorizes the human organoids market by product (Liver models, kidney models, pancreatic models, colorectal models, heart models, lung models, other products),  by source (adult stem cells, induced pluripotent stem cells, embryonic stem cells, other sources), by type (ready-to-use products, customizable products), by culture method (air-liquid interface culture, suspension culture, matrigel matrix culture, 3d bioprinting culture, and other culture methods), by disease area (oncology, liver diseases, gastrointestinal diseases, cardiovascular diseases, infectious diseases, neurological disorders, and other disease areas), by apllication (developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, regenerative medicine, and other applications), by end user (pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the human organoids market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the human organoids market. Competitive analysis of upcoming startups in the human organoids market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall human organoids market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing focus on developing alternatives to animal testing, rising R&D funding and venture capital investments, increasing research on organoids, increasing prevalence of non-alcoholic fatty liver disease , and need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure), opportunities (Increasing focus on drug discovery activities, rising demand for organ transplantation, and growth opportunities in emerging economies), restraints (Issues related to incorporating organoids into existing workflows), and challenges (Dearth of skilled professionals) influencing the growth of the human organoids market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the human organoids market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the human organoids market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human organoids market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), and HUB Organoids BV (Netherlands).

Table of Contents

1               INTRODUCTION              38

1.1           STUDY OBJECTIVES       38

1.2           MARKET DEFINITION   38

1.3           STUDY SCOPE   39

1.3.1        MARKETS COVERED & REGIONAL SCOPE             39

1.3.2        INCLUSIONS & EXCLUSIONS       40

1.3.3        YEARS CONSIDERED      41

1.3.4        CURRENCY CONSIDERED            41

1.4           STAKEHOLDERS               41

1.5           SUMMARY OF CHANGES               42

2               RESEARCH METHODOLOGY       43

2.1           RESEARCH DATA              43

2.2           RESEARCH APPROACH  43

2.2.1        SECONDARY DATA          44

2.2.1.1    Key data from secondary sources       44

2.2.2        PRIMARY DATA 45

2.2.2.1    Primary sources    46

2.2.2.2    Key data from primary sources           46

2.2.2.3    Key industry insights           48

2.2.2.4    Breakdown of primary interviews      48

2.3           MARKET SIZE ESTIMATION         49

2.3.1        BOTTOM-UP APPROACH              49

2.3.1.1    Approach 1: Company revenue estimation approach     50

2.3.1.2    Approach 2: Presentations of companies and primary interviews                 50

2.3.1.3    Growth forecasts  50

2.3.1.4    CAGR projections                 51

2.3.2        TOP-DOWN APPROACH                51

2.4           MARKET BREAKDOWN AND DATA TRIANGULATION                 52

2.5           MARKET SHARE                53

2.6           ASSUMPTIONS & LIMITATIONS 54

2.6.1        STUDY ASSUMPTIONS  54

2.6.2        GROWTH RATE ASSUMPTIONS 54

2.6.3        LIMITATIONS    55

2.7           RISK ASSESSMENT           55

2.7.1        RISK ASSESSMENT: HUMAN ORGANOIDS MARKET                 55

3               EXECUTIVE SUMMARY  56

4               PREMIUM INSIGHTS       63

4.1           HUMAN ORGANOIDS MARKET OVERVIEW           63

4.2           HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029        63

4.3           HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029        64

4.4           HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029                 64

4.5           HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029 65

4.6           HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029        65

4.7           HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              66

5               MARKET OVERVIEW       67

5.1           INTRODUCTION              67

5.2           MARKET DYNAMICS       67

5.2.1        DRIVERS               68

5.2.1.1    Growing focus on developing alternatives to animal testing                 68

5.2.1.2    Rising R&D funding and venture capital investments    69

5.2.1.3    Increasing research on organoids       70

5.2.1.4    Increasing prevalence of non-alcoholic fatty liver disease                 70

5.2.1.5    Need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure             71

5.2.2        RESTRAINTS      72

5.2.2.1    Issues related to incorporating organoids into existing workflows                 72

5.2.3        OPPORTUNITIES              72

5.2.3.1    Increasing focus on drug discovery activities   72

5.2.3.2    Rising demand for organ transplantation          74

5.2.3.3    Growth opportunities in emerging economies 75

5.2.4        CHALLENGES    75

5.2.4.1    Dearth of skilled professionals            75

5.3           PRICING ANALYSIS          76

5.3.1        AVERAGE SELLING PRICE, BY PRODUCT               76

5.3.2        AVERAGE SELLING PRICE, BY REGION   77

5.4           PATENT ANALYSIS          78

5.4.1        LIST OF MAJOR PATENTS             79

5.5           VALUE CHAIN ANALYSIS               80

5.6           SUPPLY CHAIN ANALYSIS             82

5.7           TRADE ANALYSIS             83

5.7.1        IMPORT DATA (HS CODE 3002) 83

5.7.2        EXPORT DATA (HS CODE 3002) 84

5.8           ECOSYSTEM ANALYSIS  84

5.8.1        ROLE IN ECOSYSTEM     85

5.9           PORTER’S FIVE FORCES ANALYSIS           86

5.9.1        THREAT OF NEW ENTRANTS      87

5.9.2        THREAT OF SUBSTITUTES          87

5.9.3        BARGAINING POWER OF BUYERS             87

5.9.4        BARGAINING POWER OF SUPPLIERS       88

5.9.5        INTENSITY OF COMPETITIVE RIVALRY 88

5.10         KEY STAKEHOLDERS AND BUYING CRITERIA     88

5.10.1      KEY STAKEHOLDERS IN BUYING PROCESS           88

5.10.2      KEY BUYING CRITERIA  89

5.11         REGULATORY LANDSCAPE         89

5.11.1      KEY REGULATIONS         90

5.11.1.1  North America      90

5.11.1.1.1                US           90

5.11.1.1.2                Canada   90

5.11.1.2  Europe   90

5.11.1.3  Asia Pacific            91

5.11.1.3.1                China      91

5.11.1.3.2                Japan      91

5.11.1.3.3                India       91

5.11.1.4  Latin America       91

5.11.1.4.1                Brazil      91

5.11.1.4.2                Mexico   92

5.11.1.5  Middle East & Africa            92

5.11.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             92

5.11.2.1  North America      92

5.11.2.2  Europe   93

5.11.2.3  Asia Pacific            93

5.11.2.4  Latin America       94

5.11.2.5  Rest of the world  94

5.12         TECHNOLOGY ANALYSIS             94

5.12.1      KEY TECHNOLOGIES     95

5.12.1.1  Stem Cell Technology          95

5.12.2      COMPLEMENTARY TECHNOLOGIES       95

5.12.2.1  3D Bioprinting      95

5.12.3      ADJACENT TECHNOLOGIES       95

5.12.3.1  Organ-on-a-Chip 95

5.13         KEY CONFERENCES AND EVENTS IN 2024–2025   96

5.14         TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            97

5.15         INVESTMENT AND FUNDING SCENARIO               97

5.16         CASE STUDY ANALYSIS 98

5.16.1      CASE STUDY 1: EVALUATION OF PATIENT-DERIVED ORGANOIDS FOR DRUG SENSITIVITY TESTING IN METASTATIC COLORECTAL CANCER WITH LIMITED TREATMENT OPTIONS                 98

5.16.2      CASE STUDY 2: DEVELOPING STABLE ORGANOID MODELS FROM GASTRIC CANCER TISSUES FOR PERSONALIZED MEDICINE AND DRUG SCREENING          99

5.16.3      CASE STUDY 3: OPTIMAL CULTIVATION PERIODS FOR BLADDER CANCER ORGANOIDS BASED ON TRANSCRIPTOMIC PLASTICITY        99

5.17         IMPACT OF AI ON HUMAN ORGANOIDS MARKET                 100

5.17.1      KEY USE CASES 101

6               HUMAN ORGANOIDS MARKET, BY PRODUCT    102

6.1           INTRODUCTION              103

6.2           LIVER MODELS 103

6.2.1        2D LIVER MODELS           107

6.2.1.1    Fresh hepatocytes 108

6.2.1.1.1 Increased drug metabolism studies to drive market        108

6.2.1.2    Cryopreserved hepatocytes 109

6.2.1.2.1 High quality and response to support market growth     109

6.2.1.3    Other 2D liver models         110

6.2.2        3D LIVER MODELS           111

6.2.2.1    Liver organoids     112

6.2.2.1.1 Support for determining pharmacology and hepatic toxicity of drugs to treat NAFLD         112

6.2.2.2    3D bioprinted liver models 113

6.2.2.2.1 Increased use in drug discovery to propel market growth                 113

6.2.2.3    Liver spheroids     114

6.2.2.3.1 Need for better approaches in drug discovery to promote adoption of spheroids          114

6.2.2.4    Liver-on-a-chip     115

6.2.2.4.1 Stricter regulations on animal testing to promote adoption of in vitro systems like liver-on-a-chip       115

6.2.2.5    Other 3D liver models         116

6.3           KIDNEY MODELS             117

6.3.1        2D KIDNEY MODELS       120

6.3.1.1    Fresh kidney cells 121

6.3.1.1.1 Accurate representation and functionality to support usage                 121

6.3.1.2    Cryopreserved kidney cells 122

6.3.1.2.1 Long-term storage benefits to drive market     122

6.3.1.3    Other 2D kidney models     123

6.3.2        3D KIDNEY MODELS       123

6.3.2.1    Kidney organoids 124

6.3.2.1.1 Increasing incidence of chronic kidney disease to boost market growth    124

6.3.2.2    3D bioprinted kidney models             125

6.3.2.2.1 High cost of bioprinting to hinder market growth           125

6.3.2.3    Kidney spheroids  126

6.3.2.3.1 Feasibility of studying challenging kidney diseases to drive adoption 126

6.3.2.4    Other 3D kidney models     126

6.4           PANCREATIC MODELS  127

6.4.1        2D PANCREATIC MODELS            130

6.4.1.1    Fresh pancreatic cells           131

6.4.1.1.1 High responsiveness to stimuli to support demand        131

6.4.1.2    Cryopreserved pancreatic cells           132

6.4.1.2.1 Potential use of cryopreserved cells in regenerative therapies and transplantation to increase demand  132

6.4.1.3    Other 2D pancreatic models               133

6.4.2        3D PANCREATIC MODELS            133

6.4.2.1    Pancreatic organoids            134

6.4.2.1.1 Increasing prevalence of diabetes and pancreatic cancer to drive uptake of pancreatic organoids           134

6.4.2.2    3D bioprinted pancreatic models       135

6.4.2.2.1 Precise fabrication and close resemblance to native architecture to drive adoption  135

6.4.2.3    Pancreatic spheroids            136

6.4.2.3.1 Improved methods for 3D cell culture to promote spheroid formation and support market growth               136

6.4.2.4    Other 3D pancreatic models               137

6.5           COLORECTAL MODELS 137

6.5.1        2D COLORECTAL MODELS          140

6.5.1.1    Fresh colorectal cells            141

6.5.1.1.1 Increasing incidence of colorectal cancer worldwide to heighten demand for fresh cells          141

6.5.1.2    Cryopreserved colorectal cells            142

6.5.1.2.1 Ability to thaw and culture cells on demand to support efficient research process, reducing need for continuous tissue sourcing  142

6.5.1.3    Other 2D colorectal models                143

6.5.2        3D COLORECTAL MODELS          144

6.5.2.1    Colorectal organoids            145

6.5.2.1.1 Drive to enhance therapeutic interventions will support growth                 145

6.5.2.2    3D bioprinted colorectal models        146

6.5.2.2.1 Increasing bioburden of colorectal cancer to drive market growth                 146

6.5.2.3    Colorectal spheroids             147

6.5.2.3.1 Advantages in determining disease mechanisms and drug testing to drive adoption  147

6.5.2.4    Other 3D colorectal models                147

6.6           HEART MODELS               148

6.6.1        2D HEART MODELS        151

6.6.1.1    Fresh heart cells   152

6.6.1.1.1 Importance in regenerative medicine applications to support adoption 152

6.6.1.2    Cryopreserved heart cells    152

6.6.1.2.1 On-demand access for clinical or research use to drive uptake of cryopreserved cells               152

6.6.1.3    Other 2D heart models       153

6.6.2        3D HEART MODELS        154

6.6.2.1    Heart organoids    155

6.6.2.1.1 Rising demand in cardiogenesis research to propel market growth                 155

6.6.2.2    3D bioprinted heart models                155

6.6.2.2.1 High production costs to hinder adoption        155

6.6.2.3    Heart spheroids    156

6.6.2.3.1 Challenges in controlling spheroid morphology to restrain growth                 156

6.6.2.4    Other 3D heart models       157

6.7           LUNG MODELS 158

6.7.1        2D LUNG MODELS           161

6.7.1.1    Fresh lung cells     162

6.7.1.1.1 Use of fresh lung cells gaining momentum due to their ability to accurately replicate native lung environment   162

6.7.1.2    Cryopreserved lung cells     163

6.7.1.2.1 Advancements in slicing and cryopreservation to enable creation of thousands of hPCLS from a single lung       163

6.7.1.3    Other 2D lung models         164

6.7.2        3D LUNG MODELS           164

6.7.2.1    Lung organoids     165

6.7.2.1.1 Increased adoption in biological research areas to boost market growth    165

6.7.2.2    3D bioprinted lung models 166

6.7.2.2.1 Advancements in bioinks to support uptake of 3D bioprinted lung models    166

6.7.2.3    Lung spheroids     167

6.7.2.3.1 Advantages of physiologically relevant environments for evaluating drug efficacy and toxicity to support usage   167

6.7.2.4    Other 3D lung models         168

6.8           OTHER PRODUCTS         168

6.8.1        2D MODELS (OTHER PRODUCTS)            171

6.8.1.1    Fresh cells (other products)                172

6.8.1.1.1 New techniques for isolating and preserving fresh cells to help enhance quality of research 172

6.8.1.2    Cryopreserved cells (other products)                173

6.8.1.2.1 Long-term storage benefits and advancements in research to support adoption  173

6.8.1.3    Other 2D models 174

6.8.2        3D MODELS (OTHER PRODUCTS)            175

6.8.2.1    Organoids (other products)                176

6.8.2.1.1 Growing focus on collaboration fosters innovation in organoid development          176

6.8.2.2    3D bioprinted models (other products)            177

6.8.2.2.1 Lack of suitable bioinks for 3D bioprinting applications to hamper market growth        177

6.8.2.3    Spheroids (other products) 178

6.8.2.3.1 Predictive environment for assessing efficacy and safety to support adoption  178

6.8.2.4    Other 3D models (other products)   179

7               HUMAN ORGANOIDS MARKET, BY SOURCE         180

7.1           INTRODUCTION              181

7.2           ADULT STEM CELLS       181

7.2.1        ADULT STEM CELLS TO HOLD LARGEST SHARE OF MARKET, BY SOURCE     181

7.3           INDUCED PLURIPOTENT STEM CELLS  184

7.3.1        GROWING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE UPTAKE OF IPSCS              184

7.4           EMBRYONIC STEM CELLS             186

7.4.1        ETHICAL CONCERNS ASSOCIATED WITH ESCS TO HINDER MARKET GROWTH         186

7.5           OTHER SOURCES             189

8               HUMAN ORGANOIDS MARKET, BY TYPE               192

8.1           INTRODUCTION              193

8.2           READY-TO-USE PRODUCTS        193

8.2.1        MASS PRODUCTION OF READY-TO-USE PRODUCTS TO DRIVE ADOPTION           193

8.3           CUSTOMIZABLE PRODUCTS       196

8.3.1        ADVANCEMENTS IN 3D BIOPRINTING TO PROPEL MARKET GROWTH          196

9               HUMAN ORGANOIDS MARKET, BY CULTURE METHOD                 200

9.1           INTRODUCTION              201

9.2           MATRIGEL MATRIX CULTURE    201

9.2.1        LONG-STANDING USE AND EFFECTIVENESS IN GROWING ORGANOIDS TO ENSURE ADOPTION               201

9.3           AIR-LIQUID INTERFACE CULTURE           204

9.3.1        INCREASING PREVALENCE OF DISEASES AFFECTING EPITHELIAL TISSUES TO DRIVE ADOPTION        204

9.4           SUSPENSION CULTURE 206

9.4.1        COST-EFFECTIVENESS OF SUSPENSION CULTURE TO DRIVE MARKET 206

9.5           3D BIOPRINTING CULTURE        209

9.5.1        RISING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH           209

9.6           OTHER CULTURE METHODS     211

10            HUMAN ORGANOIDS MARKET, BY DISEASE AREA                 214

10.1         INTRODUCTION              215

10.2         ONCOLOGY        215

10.2.1      GROWING FOCUS ON PERSONALIZED MEDICINE IN ONCOLOGY TO DRIVE DEMAND FOR CANCER ORGANOIDS                 215

10.3         LIVER DISEASES                218

10.3.1      INCREASING INCIDENCE OF LIVER-RELATED CONDITIONS TO DRIVE DEMAND FOR EFFECTIVE RESEARCH MODELS               218

10.4         GASTROINTESTINAL DISEASES 220

10.4.1      WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET        220

10.5         CARDIOVASCULAR DISEASES    223

10.5.1      RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 223

10.6         INFECTIOUS DISEASES 225

10.6.1      USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH               225

10.7         NEUROLOGICAL DISORDERS     228

10.7.1      GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS                 228

10.8         OTHER DISEASE AREAS 230

11            HUMAN ORGANOIDS MARKET, BY APPLICATION                 233

11.1         INTRODUCTION              234

11.2         DEVELOPMENTAL BIOLOGY      234

11.2.1      TECHNOLOGICAL ADVANCEMENTS IN STEM CELL RESEARCH TO BOOST MARKET GROWTH            234

11.3         DRUG TOXICITY & EFFICACY TESTING 237

11.3.1      INCREASED DRUG DEVELOPMENT COSTS TO DRIVE GROWTH             237

11.4         DISEASE PATHOLOGY   239

11.4.1      INCREASED DEMAND FOR ADVANCED IN VITRO DISEASE STUDIES TO AUGMENT MARKET GROWTH       239

11.5         PERSONALIZED MEDICINE          242

11.5.1      HIGH COST AND INSUFFICIENT DATA TO HAMPER MARKET GROWTH          242

11.6         REGENERATIVE MEDICINE         244

11.6.1      INCREASING FUNDING ACTIVITIES TO PROPEL MARKET GROWTH          244

11.7         OTHER APPLICATIONS 247

12            HUMAN ORGANOIDS MARKET, BY END USER     250

12.1         INTRODUCTION              251

12.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 251

12.2.1      INCREASING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET GROWTH         251

12.3         CONTRACT RESEARCH ORGANIZATIONS             254

12.3.1      INCREASING OUTSOURCING OF CLINICAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH         254

12.4         ACADEMIC & RESEARCH INSTITUTES    256

12.4.1      RISING GOVERNMENT FUNDING AND INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET                 256

12.5         OTHER END USERS         259

13            HUMAN ORGANOIDS MARKET, BY REGION         262

13.1         INTRODUCTION              263

13.2         NORTH AMERICA             263

13.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 264

13.2.2      US           268

13.2.2.1  Rising prevalence of chronic respiratory diseases and organ transplants to expedite growth           268

13.2.3      CANADA               272

13.2.3.1  Growing incidence of cancer and investments in disease diagnostics & life science research to drive market         272

13.3         EUROPE               277

13.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      278

13.3.2      GERMANY           282

13.3.2.1  Higher healthcare spending and organ transplants to favor market growth       282

13.3.3      UK          286

13.3.3.1  Rising disease prevalence to drive market growth           286

13.3.4      FRANCE                290

13.3.4.1  Increasing availability of advanced medical technologies to support market growth        290

13.3.5      ITALY    294

13.3.5.1  Modernization of healthcare infrastructure to support market                 294

13.3.6      SPAIN    297

13.3.6.1  Rising incidences of cancer to drive demand   297

13.3.7      REST OF EUROPE             301

13.4         ASIA PACIFIC     304

13.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 305

13.4.2      CHINA  310

13.4.2.1  Healthcare infrastructure improvements to support market growth in China    310

13.4.3      JAPAN   313

13.4.3.1  Rising biomedical & medical research to support market growth                 313

13.4.4      INDIA    317

13.4.4.1  Large patient population and developing healthcare sector to drive market          317

13.4.5      AUSTRALIA         321

13.4.5.1  Rising private and public funding for research activities to drive market    321

13.4.6      SOUTH KOREA  325

13.4.6.1  Favorable government policies to fuel market growth    325

13.4.7      REST OF ASIA PACIFIC   329

13.5         LATIN AMERICA                332

13.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 334

13.5.2      BRAZIL 337

13.5.2.1  Growing pharmaceuticals market and budget allocations to boost market    337

13.5.3      MEXICO                341

13.5.3.1  Booming medical tourism to support growth   341

13.5.4      REST OF LATIN AMERICA             344

13.6         MIDDLE EAST & AFRICA                348

13.6.1      GROWING FOCUS ON IMPROVING QUALITY OF LIFE TO DRIVE MARKET 348

13.6.2      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 349

13.7         GCC COUNTRIES              352

13.7.1      RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO AUGMENT MARKET         352

13.7.2      MACROECONOMIC OUTLOOK FOR GCC COUNTRIES                 353

14            COMPETITIVE LANDSCAPE         357

14.1         INTRODUCTION              357

14.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            357

14.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET  357

14.3         REVENUE ANALYSIS, 2021–2023  359

14.4         MARKET SHARE ANALYSIS, 2023                 360

14.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 361

14.5.1      STARS   361

14.5.2      EMERGING LEADERS     362

14.5.3      PERVASIVE PLAYERS      362

14.5.4      PARTICIPANTS 362

14.5.5      COMPANY FOOTPRINT, KEY PLAYERS, 2023         363

14.5.5.1  Company footprint               363

14.5.5.2  Region footprint   363

14.5.5.3  Product footprint  364

14.5.5.4  Source footprint    365

14.5.5.5  Application footprint            365

14.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        366

14.6.1      PROGRESSIVE COMPANIES         366

14.6.2      RESPONSIVE COMPANIES            366

14.6.3      DYNAMIC COMPANIES  366

14.6.4      STARTING BLOCKS         366

14.6.5      COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023   367

14.7         COMPANY VALUATION AND FINANCIAL METRICS                 368

14.8         BRAND/PRODUCT COMPARATIVE ANALYSIS     369

14.8.1      BIOIVT 369

14.8.2      BECYTES BIOTECHNOLOGIES   369

14.9         COMPETITIVE SCENARIO             369

14.9.1      PRODUCT LAUNCHES   370

14.9.2      DEALS  370

15            COMPANY PROFILES      372

15.1         KEY PLAYERS     372

15.1.1      THERMO FISHER SCIENTIFIC INC.            372

15.1.1.1  Business overview 372

15.1.1.2  Products offered   373

15.1.1.3  Recent developments           374

15.1.1.3.1                Product launches  374

15.1.1.3.2                Deals      375

15.1.1.4  MnM view              375

15.1.1.4.1                Right to win           375

15.1.1.4.2                Strategic choices   375

15.1.1.4.3                Weaknesses and competitive threats 376

15.1.2      CORNING INCORPORATED         377

15.1.2.1  Business overview 377

15.1.2.2  Products offered   378

15.1.2.3  Recent developments           379

15.1.2.3.1                Deals      379

15.1.2.4  MnM view              379

15.1.2.4.1                Right to win           379

15.1.2.4.2                Strategic choices   380

15.1.2.4.3                Weaknesses and competitive threats 380

15.1.3      MERCK KGAA    381

15.1.3.1  Business overview 381

15.1.3.2  Products offered   382

15.1.3.3  Recent developments           383

15.1.3.3.1                Deals      383

15.1.3.3.2                Expansions             383

15.1.3.4  MnM view              383

15.1.3.4.1                Right to win           383

15.1.3.4.2                Strategic choices   383

15.1.3.4.3                Weaknesses and competitive threats 383

15.1.4      BIOIVT 384

15.1.4.1  Business overview 384

15.1.4.2  Products offered   384

15.1.4.3  Recent developments           388

15.1.4.3.1                Deals      388

15.1.4.4  MnM view              389

15.1.4.4.1                Right to win           389

15.1.4.4.2                Strategic choices   389

15.1.4.4.3                Weaknesses and competitive threats 389

15.1.5      HUB ORGANOIDS BV     390

15.1.5.1  Business overview 390

15.1.5.2  Products offered   390

15.1.5.3  Recent developments           390

15.1.5.3.1                Deals      390

15.1.5.4  MnM view              391

15.1.5.4.1                Right to win           391

15.1.5.4.2                Strategic choices   391

15.1.5.4.3                Weaknesses and competitive threats 391

15.1.6      BICO      392

15.1.6.1  Business overview 392

15.1.6.2  Products offered   393

15.1.6.3  Recent developments           394

15.1.6.3.1                Product launches  394

15.1.6.3.2                Deals      394

15.1.6.3.3                Other developments             394

15.1.7      BECYTES BIOTECHNOLOGIES   395

15.1.7.1  Business overview 395

15.1.7.2  Products offered   395

15.1.8      INSPHERO           396

15.1.8.1  Business overview 396

15.1.8.2  Products offered   396

15.1.8.3  Recent developments           397

15.1.8.3.1                Deals      397

15.1.9      GBA GROUP       398

15.1.9.1  Business overview 398

15.1.9.2  Products offered   398

15.1.9.3  Recent developments           398

15.1.9.3.1                Deals      398

15.1.10   KIRKSTALL LTD.               399

15.1.10.1                 Business overview 399

15.1.10.2                 Products offered   399

15.1.11   MIMETAS BV      400

15.1.11.1                 Business overview 400

15.1.11.2                 Products offered   400

15.1.11.3                 Recent developments           401

15.1.11.3.1             Product launches  401

15.1.11.3.2             Deals      401

15.1.12   NEUROMICS       402

15.1.12.1                 Business overview 402

15.1.12.2                 Products offered   402

15.1.13   PRIMACYT CELL CULTURE TECHNOLOGY GMBH                 404

15.1.13.1                 Business overview 404

15.1.13.2                 Products offered   404

15.1.14   STEMCELL TECHNOLOGIES       405

15.1.14.1                 Business overview 405

15.1.14.2                 Products offered   405

15.1.14.3                 Recent developments           406

15.1.14.3.1             Expansions             406

15.2         OTHER PLAYERS              407

15.2.1      ACROBIOSYSTEMS          407

15.2.2      BIOPREDIC INTERNATIONAL     408

15.2.3      CN BIO INNOVATIONS LTD.       408

15.2.4      CYPRIO 409

15.2.5      EMULATE, INC. 410

15.2.6      KERAFAST, INC.                411

15.2.7      PANDORUM TECHNOLOGIES PVT. LTD.               411

15.2.8      CYFUSE BIOMEDICAL KK              412

15.2.9      NEYROBLASTGX LLC      413

15.2.10   3DNAMICS INC. 414

15.2.11   DEFINIGEN LIMITED     415

16            APPENDIX           416

16.1         DISCUSSION GUIDE        416

16.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                423

16.3         CUSTOMIZATION OPTIONS        425

16.4         RELATED REPORTS         425

16.5         AUTHOR DETAILS           426

LIST OF TABLES

TABLE 1                INVESTMENTS AND FUNDS FOR HUMAN ORGANOID RESEARCH  69

TABLE 2                RESEARCH PROJECTS AND ACTIVITIES 70

TABLE 3                AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY TYPE,

2022–2024              76

TABLE 4                AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY REGION,

2022–2024              77

TABLE 5                HUMAN ORGANOIDS MARKET: LIST OF MAJOR PATENTS, 2022–2023        79

TABLE 6                IMPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES,

WHETHER OR NOT MODIFIED, 2019–2023 (USD MILLION)                 83

TABLE 7                EXPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES,

WHETHER OR NOT MODIFIED, BY COUNTRY, 2019–2023 (USD MILLION)            84

TABLE 8                HUMAN ORGANOIDS MARKET: ROLE IN ECOSYSTEM       85

TABLE 9                HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES                87

TABLE 10              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS (%)  89

TABLE 11              KEY BUYING CRITERIA FOR HUMAN ORGANOIDS, BY TYPE   89

TABLE 12              NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  92

TABLE 13              EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  93

TABLE 14              ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  93

TABLE 15              LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  94

TABLE 16              REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  94

TABLE 17              HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY CONFERENCES

AND EVENTS, JANUARY 2024–DECEMBER 2025    96

TABLE 18              HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)            103

TABLE 19              LIVER MODELS: KEY PRODUCTS OFFERED, BY COMPANY           104

TABLE 20              LIVER AND INTRAHEPATIC BILE DUCT CANCER INCIDENCE, 2022               104

TABLE 21              HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY REGION,

2022–2029 (USD MILLION)            105

TABLE 22              NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022–2029 (USD MILLION)            105

TABLE 23              EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY,

2022–2029 (USD MILLION)            106

TABLE 24              ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 106

TABLE 25              LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 107

TABLE 26              HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY TYPE,

2022–2029 (USD MILLION)            107

TABLE 27              2D LIVER MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       108

TABLE 28              2D LIVER MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION) 108

TABLE 29              FRESH HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY               109

TABLE 30              FRESH HEPATOCYTES MARKET, BY REGION, 2022–2029 (USD MILLION)            109

TABLE 31              CRYOPRESERVED HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY      110

TABLE 32              CRYOPRESERVED HEPATOCYTES MARKET, BY REGION,

2022–2029 (USD MILLION)            110

TABLE 33              OTHER 2D LIVER MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            111

TABLE 34              3D LIVER MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       112

TABLE 35              3D LIVER MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION) 112

TABLE 36              LIVER ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       113

TABLE 37              3D BIOPRINTED LIVER MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)          114

TABLE 38              LIVER SPHEROIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       115

TABLE 39              LIVER-ON-A CHIP MARKET, BY REGION, 2022–2029 (USD MILLION)       116

TABLE 40              OTHER 3D LIVER MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            116

TABLE 41              KIDNEY MODELS: KEY PRODUCTS OFFERED, BY COMPANY           117

TABLE 42              KIDNEY CANCER INCIDENCE, 2022           117

TABLE 43              HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY REGION,

2022–2029 (USD MILLION)            118

TABLE 44              NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               118

TABLE 45              EUROPE: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 119

TABLE 46              ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 119

TABLE 47              LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               120

TABLE 48              HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY TYPE,

2022–2029 (USD MILLION)            120

TABLE 49              2D KIDNEY MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       121

TABLE 50              2D KIDNEY MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)       121

TABLE 51              FRESH KIDNEY CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)            122

TABLE 52              CRYOPRESERVED KIDNEY CELLS MARKET, BY REGION,

2022–2029 (USD MILLION)            122

TABLE 53              OTHER 2D KIDNEY MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)          123

TABLE 54              3D KIDNEY MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       124

TABLE 55              3D KIDNEY MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)       124

TABLE 56              KIDNEY ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)            125

TABLE 57              3D BIOPRINTED KIDNEY MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            125

TABLE 58              KIDNEY SPHEROIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       126

TABLE 59              OTHER 3D KIDNEY MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)          127

TABLE 60              PANCREATIC MODELS: KEY PRODUCTS OFFERED, BY COMPANY               127

TABLE 61              PANCREATIC CANCER INCIDENCE, 2022                 128

TABLE 62              HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY REGION,

2022–2029 (USD MILLION)            128

TABLE 63              NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               128

TABLE 64              EUROPE: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 129

TABLE 65              ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               129

TABLE 66              LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               130

TABLE 67              HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY TYPE,

2022–2029 (USD MILLION)            130

TABLE 68              2D PANCREATIC MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            131

TABLE 69              2D PANCREATIC MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)            131

TABLE 70              FRESH PANCREATIC CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)          132

TABLE 71              CRYOPRESERVED PANCREATIC CELLS MARKET, BY REGION,

2022–2029 (USD MILLION)            132

TABLE 72              OTHER 2D PANCREATIC MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            133

TABLE 73              3D PANCREATIC MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            134

TABLE 74              3D PANCREATIC MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)            134

TABLE 75             PANCREATIC ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)            135

TABLE 76              3D BIOPRINTED PANCREATIC MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            136

TABLE 77              PANCREATIC SPHEROIDS MARKET, BY REGION, 2022–2029 (USD MILLION)            136

TABLE 78              OTHER 3D PANCREATIC MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            137

TABLE 79              COLORECTAL MODELS: KEY PRODUCTS OFFERED, BY COMPANY               138

TABLE 80              COLORECTAL CANCER INCIDENCE, 2022                 138

TABLE 81              HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY REGION,

2022–2029 (USD MILLION)            138

TABLE 82              NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               139

TABLE 83              EUROPE: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022–2029 (USD MILLION)            139

TABLE 84              ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               139

TABLE 85              LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               140

TABLE 86              HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY TYPE,

2022–2029 (USD MILLION)            140

TABLE 87             2D COLORECTAL MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            141

TABLE 88              2D COLORECTAL MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)            141

TABLE 89              FRESH COLORECTAL CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)          142

TABLE 90              CRYOPRESERVED COLORECTAL CELLS MARKET, BY REGION,

2022–2029 (USD MILLION)            143

TABLE 91              OTHER 2D COLORECTAL MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            143

TABLE 92             3D COLORECTAL MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            144

TABLE 93              3D COLORECTAL MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)            144

TABLE 94              COLORECTAL ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)          145

TABLE 95              3D BIOPRINTED COLORECTAL MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            146

TABLE 96             COLORECTAL SPHEROIDS MARKET, BY REGION, 2022–2029 (USD MILLION)            147

TABLE 97              OTHER 3D COLORECTAL MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            148

TABLE 98              HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY REGION,

2022–2029 (USD MILLION)            149

TABLE 99              NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS,

BY COUNTRY, 2022–2029 (USD MILLION)               149

TABLE 100            EUROPE: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY,

2022–2029 (USD MILLION)            149

TABLE 101            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 150

TABLE 102            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 150

TABLE 103            HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY TYPE,

2022–2029 (USD MILLION)            150

TABLE 104            2D HEART MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       151

TABLE 105            2D HEART MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)       151

TABLE 106            FRESH HEART CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)            152

TABLE 107            CRYOPRESERVED HEART CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)          153

TABLE 108            OTHER 2D HEART MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)          153

TABLE 109            3D HEART MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       154

TABLE 110            3D HEART MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION)       154

TABLE 111            HEART ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       155

TABLE 112            3D BIOPRINTED HEART MODELS MARKET, BY REGION,

2022–2029 (USD MILLION)            156

TABLE 113            HEART SPHEROIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       157

TABLE 114            OTHER 3D HEART MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)          157

TABLE 115            LUNG MODELS: KEY PRODUCTS OFFERED, BY COMPANY           158

TABLE 116            LUNG CANCER INCIDENCE,2022                158

TABLE 117            HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY REGION,

2022–2029 (USD MILLION)            159

TABLE 118            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022–2029 (USD MILLION)            159

TABLE 119            EUROPE: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY,

2022–2029 (USD MILLION)            160

TABLE 120            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 160

TABLE 121            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022–2029 (USD MILLION)                 161

TABLE 122            HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY TYPE,

2022–2029 (USD MILLION)            161

TABLE 123            2D LUNG MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       162

TABLE 124            2D LUNG MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION) 162

TABLE 125            FRESH LUNG CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)       163

TABLE 126            CRYOPRESERVED LUNG CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)          163

TABLE 127            OTHER 2D LUNG MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            164

TABLE 128            3D LUNG MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)       165

TABLE 129            3D LUNG MODELS MARKET, BY TYPE, 2022–2029 (USD MILLION) 165

TABLE 130            LUNG ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       166

TABLE 131            3D BIOPRINTED LUNG MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)          167

TABLE 132            LUNG SPHEROIDS MARKET, BY REGION, 2022–2029 (USD MILLION)       167

TABLE 133            OTHER 3D LUNG MODELS MARKET, BY REGION, 2022–2029 (USD MILLION)            168

TABLE 134            OTHER PRODUCTS: KEY PRODUCTS OFFERED, BY COMPANY    169

TABLE 135            BRAIN, CENTRAL NERVOUS SYSTEM, AND BREAST CANCER INCIDENCE, 2022           169

TABLE 136            OTHER HUMAN ORGANOID PRODUCTS MARKET, BY REGION,

2022–2029 (USD MILLION)            169

TABLE 137            NORTH AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 170

TABLE 138            EUROPE: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            170

TABLE 139            ASIA PACIFIC: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 170

TABLE 140            LATIN AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 171

TABLE 141            OTHER HUMAN ORGANOID PRODUCTS MARKET, BY TYPE,

2022–2029 (USD MILLION)            171

TABLE 142            2D MODELS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            172

TABLE 143            2D MODELS (OTHER PRODUCTS) MARKET, BY TYPE,

2022–2029 (USD MILLION)            172

TABLE 144            FRESH CELLS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            173

TABLE 145            CRYOPRESERVED CELLS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            174

TABLE 146            OTHER 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            174

TABLE 147            3D MODELS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            175

TABLE 148            3D MODELS (OTHER PRODUCTS) MARKET, BY TYPE, 2022–2029 (USD MILLION)                176

TABLE 149            ORGANOIDS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            176

TABLE 150            3D BIOPRINTED MODELS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            177

TABLE 151            SPHEROIDS (OTHER PRODUCTS) MARKET, BY REGION, 2022–2029 (USD MILLION)          178

TABLE 152            OTHER 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION,

2022–2029 (USD MILLION)            179

TABLE 153            HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)            181

TABLE 154            ADULT STEM CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)       182

TABLE 155          NORTH AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            182

TABLE 156            EUROPE: ADULT STEM CELLS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     183

TABLE 157            ASIA PACIFIC: ADULT STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            183

TABLE 158            LATIN AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            183

TABLE 159            INDUCED PLURIPOTENT STEM CELLS: KEY PRODUCTS OFFERED, BY COMPANY      184

TABLE 160            INDUCED PLURIPOTENT STEM CELLS MARKET, BY REGION,

2022–2029 (USD MILLION)            185

TABLE 161            NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 185

TABLE 162            EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            185

TABLE 163            ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            186

TABLE 164            LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 186

TABLE 165            EMBRYONIC STEM CELLS MARKET, BY REGION, 2022–2029 (USD MILLION)            187

TABLE 166            NORTH AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            187

TABLE 167            EUROPE: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            188

TABLE 168            ASIA PACIFIC: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            188

TABLE 169            LATIN AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            189

TABLE 170            OTHER SOURCES: KEY PRODUCTS OFFERED, BY COMPANY           189

TABLE 171            OTHER HUMAN ORGANOID SOURCES MARKET, BY REGION,

2022–2029 (USD MILLION)            190

TABLE 172            NORTH AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 190

TABLE 173            EUROPE: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            190

TABLE 174            ASIA PACIFIC: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            191

TABLE 175            LATIN AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 191

TABLE 176            HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)       193

TABLE 177            READY-TO-USE PRODUCTS MARKET: KEY PRODUCTS, BY COMPANY           194

TABLE 178            READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY REGION,

2022–2029 (USD MILLION)            194

TABLE 179            NORTH AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               194

TABLE 180            EUROPE: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 195

TABLE 181            ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               195

TABLE 182            LATIN AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               196

TABLE 183            CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY REGION,

2022–2029 (USD MILLION)            197

TABLE 184            NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               197

TABLE 185            EUROPE: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 198

TABLE 186            ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               198

TABLE 187            LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               199

TABLE 188            HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022–2029 (USD MILLION)       201

TABLE 189            HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY REGION, 2022–2029 (USD MILLION)                 202

TABLE 190            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022–2029 (USD MILLION)            202

TABLE 191            EUROPE: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               203

TABLE 192            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               203

TABLE 193            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022–2029 (USD MILLION) 204

TABLE 194            HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY REGION, 2022–2029 (USD MILLION)                 205

TABLE 195            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022–2029 (USD MILLION)            205

TABLE 196            EUROPE: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               205

TABLE 197            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022–2029 (USD MILLION) 206

TABLE 198            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022–2029 (USD MILLION) 206

TABLE 199            HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY REGION,

2022–2029 (USD MILLION)            207

TABLE 200            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               207

TABLE 201            EUROPE: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022–2029 (USD MILLION)            208

TABLE 202            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               208

TABLE 203            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               209

TABLE 204            HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY REGION,

2022–2029 (USD MILLION)            210

TABLE 205            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022–2029 (USD MILLION)       210

TABLE 206            EUROPE: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               210

TABLE 207            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               211

TABLE 208            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE,

BY COUNTRY, 2022–2029 (USD MILLION)               211

TABLE 209            HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY REGION, 2022–2029 (USD MILLION)                 212

TABLE 210            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022–2029 (USD MILLION)       212

TABLE 211            EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS,

BY COUNTRY, 2022–2029 (USD MILLION)               212

TABLE 212            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS,

BY COUNTRY, 2022–2029 (USD MILLION)               213

TABLE 213            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022–2029 (USD MILLION)            213

TABLE 214            HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)               215

TABLE 215            INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE  216

TABLE 216          HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY REGION,

2022–2029 (USD MILLION)            216

TABLE 217            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)            217

TABLE 218            EUROPE: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY,

2022–2029 (USD MILLION)            217

TABLE 219            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY,

2022–2029 (USD MILLION)            217

TABLE 220            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)                 218

TABLE 221            HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY REGION,

2022–2029 (USD MILLION)            219

TABLE 222            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               219

TABLE 223            EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 219

TABLE 224            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 220

TABLE 225            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 220

TABLE 226            HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022–2029 (USD MILLION)            221

TABLE 227            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            221

TABLE 228            EUROPE: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               222

TABLE 229            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 222

TABLE 230            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 223

TABLE 231            HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)            224

TABLE 232            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       224

TABLE 233            EUROPE: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               224

TABLE 234            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               225

TABLE 235            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 225

TABLE 236            HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES BY REGION,

2022–2029 (USD MILLION)            226

TABLE 237            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               227

TABLE 238            EUROPE: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 227

TABLE 239            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               227

TABLE 240            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               228

TABLE 241            HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)            229

TABLE 242            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)       229

TABLE 243            EUROPE: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS,

BY COUNTRY, 2022–2029 (USD MILLION)               229

TABLE 244            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS,

BY COUNTRY, 2022–2029 (USD MILLION)               230

TABLE 245            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 230

TABLE 246            HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY REGION,

2022–2029 (USD MILLION)            231

TABLE 247            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS,

BY COUNTRY, 2022–2029 (USD MILLION)               231

TABLE 248            EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022–2029 (USD MILLION)            231

TABLE 249            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS,

BY COUNTRY, 2022–2029 (USD MILLION)               232

TABLE 250            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS,

BY COUNTRY, 2022–2029 (USD MILLION)               232

TABLE 251            HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)              234

TABLE 252            HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,

2022–2029 (USD MILLION)            235

TABLE 253            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)       235

TABLE 254            EUROPE: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2022–2029 (USD MILLION)               236

TABLE 255            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2022–2029 (USD MILLION)               236

TABLE 256            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2022–2029 (USD MILLION)               237

TABLE 257            HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY REGION, 2022–2029 (USD MILLION)            238

TABLE 258            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)     238

TABLE 259            EUROPE: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 238

TABLE 260            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY &

EFFICACY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)                 239

TABLE 261            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY &

EFFICACY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)                 239

TABLE 262            HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY REGION,

2022–2029 (USD MILLION)            240

TABLE 263            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY,

BY COUNTRY, 2022–2029 (USD MILLION)               240

TABLE 264            EUROPE: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)                 241

TABLE 265            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY,

BY COUNTRY, 2022–2029 (USD MILLION)               241

TABLE 266            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY,

BY COUNTRY, 2022–2029 (USD MILLION)               242

TABLE 267            HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY REGION,

2022–2029 (USD MILLION)            243

TABLE 268            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)       243

TABLE 269            EUROPE: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE,

BY COUNTRY, 2022–2029 (USD MILLION)               243

TABLE 270            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE,

BY COUNTRY, 2022–2029 (USD MILLION)               244

TABLE 271            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE,

BY COUNTRY, 2022–2029 (USD MILLION)               244

TABLE 272            HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY REGION,

2022–2029 (USD MILLION)          245

TABLE 273            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)       245

TABLE 274            EUROPE: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE,

BY COUNTRY, 2022–2029 (USD MILLION)               246

TABLE 275            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE,

BY COUNTRY, 2022–2029 (USD MILLION)               246

TABLE 276            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE,

BY COUNTRY, 2022–2029 (USD MILLION)               247

TABLE 277            HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY REGION,

2022–2029 (USD MILLION)            247

TABLE 278            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)               248

TABLE 279            EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            248

TABLE 280            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)               248

TABLE 281            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)               249

TABLE 282            HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)            251

TABLE 283            HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)          252

TABLE 284            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)   252

TABLE 285            EUROPE: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL &

BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)            253

TABLE 286            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)     253

TABLE 287            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)     254

TABLE 288            HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,

BY REGION, 2022–2029 (USD MILLION)   255

TABLE 289            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     255

TABLE 290            EUROPE: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)       255

TABLE 291            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            256

TABLE 292            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            256

TABLE 293            HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY REGION, 2022–2029 (USD MILLION)   257

TABLE 294            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC &

RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)            258

TABLE 295            EUROPE: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 258

TABLE 296            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)       258

TABLE 297            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)       259

TABLE 298            HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY REGION,

2022–2029 (USD MILLION)            260

TABLE 299            NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)               260

TABLE 300            EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)                 260

TABLE 301            ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)               261

TABLE 302            LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)               261

TABLE 303            HUMAN ORGANOIDS MARKET, BY REGION, 2022–2029 (USD MILLION)            263

TABLE 304            NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES

FROM 0 TO 85+ YEARS OF AGE, 2022–2045              265

TABLE 305            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            266

TABLE 306            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            266

TABLE 307            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            266

TABLE 308            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            267

TABLE 309            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            267

TABLE 310            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            267

TABLE 311            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            268

TABLE 312            NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            268

TABLE 313            US: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       270

TABLE 314            US: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     270

TABLE 315            US: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)            270

TABLE 316            US: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            271

TABLE 317            US: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022–2029 (USD MILLION)       271

TABLE 318            US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)               271

TABLE 319            US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)              272

TABLE 320            US: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                272

TABLE 321            ESTIMATED PREVALENCE OF DIABETES IN CANADA, 2022 VS. 2023   273

TABLE 322            CANADA: FIVE MOST-REPORTED CAUSES OF CANCER-RELATED MORTALITY, 2024     274

TABLE 323            CANADA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     274

TABLE 324            CANADA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         275

TABLE 325            CANADA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                275

TABLE 326            CANADA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            275

TABLE 327            CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            276

TABLE 328            CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            276

TABLE 329            CANADA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            277

TABLE 330            EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES

FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]   278

TABLE 331            EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     279

TABLE 332            EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     279

TABLE 333            EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         280

TABLE 334            EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                280

TABLE 335            EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            280

TABLE 336            EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            281

TABLE 337            EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            281

TABLE 338            EUROPE: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            282

TABLE 339            GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022             283

TABLE 340            GERMANY: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            283

TABLE 341            GERMANY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         284

TABLE 342            GERMANY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                284

TABLE 343            GERMANY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            284

TABLE 344            GERMANY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            285

TABLE 345            GERMANY: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            285

TABLE 346            GERMANY: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            286

TABLE 347            UK: INCIDENCE AND MORTALITY RATE OF HEART AND CIRCULATORY

DISEASES (CVD), 2024     286

TABLE 348            UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       287

TABLE 349            UK: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     288

TABLE 350            UK: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)            288

TABLE 351            UK: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            288

TABLE 352            UK: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            289

TABLE 353            UK: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)               289

TABLE 354            UK: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)              290

TABLE 355            UK: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                290

TABLE 356            FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022             291

TABLE 357            FRANCE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     291

TABLE 358            FRANCE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         292

TABLE 359            FRANCE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                292

TABLE 360            FRANCE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            292

TABLE 361            FRANCE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            293

TABLE 362            FRANCE: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            293

TABLE 363            FRANCE: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            294

TABLE 364            ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       295

TABLE 365            ITALY: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     295

TABLE 366            ITALY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         295

TABLE 367            ITALY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            296

TABLE 368            ITALY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            296

TABLE 369            ITALY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            296

TABLE 370            ITALY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)              297

TABLE 371            ITALY: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                297

TABLE 372            SPAIN: CANCER INCIDENCE, 2022 VS 2023                 298

TABLE 373            SPAIN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     298

TABLE 374            SPAIN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         299

TABLE 375            SPAIN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            299

TABLE 376            SPAIN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            299

TABLE 377            SPAIN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            300

TABLE 378            SPAIN: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            300

TABLE 379            SPAIN: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                301

TABLE 380            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          302

TABLE 381            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            302

TABLE 382            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            302

TABLE 383            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            303

TABLE 384            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            303

TABLE 385            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            304

TABLE 386            REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            304

TABLE 387            ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES

FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]   305

TABLE 388            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            307

TABLE 389            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            307

TABLE 390            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            308

TABLE 391            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)         308

TABLE 392            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            308

TABLE 393            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            309

TABLE 394            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            309

TABLE 395            ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            310

TABLE 396            CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       311

TABLE 397            CHINA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     311

TABLE 398            CHINA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         311

TABLE 399            CHINA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            312

TABLE 400            CHINA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            312

TABLE 401            CHINA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            312

TABLE 402            CHINA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            313

TABLE 403            CHINA: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                313

TABLE 404            JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       314

TABLE 405            JAPAN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     315

TABLE 406            JAPAN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         315

TABLE 407            JAPAN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            315

TABLE 408            JAPAN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            316

TABLE 409            JAPAN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            316

TABLE 410            JAPAN: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            317

TABLE 411            JAPAN: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                317

TABLE 412            INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       318

TABLE 413            INDIA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     319

TABLE 414            INDIA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         319

TABLE 415            INDIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)            319

TABLE 416            INDIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            320

TABLE 417            INDIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            320

TABLE 418            INDIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)              321

TABLE 419            INDIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                321

TABLE 420            AUSTRALIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022             322

TABLE 421            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            323

TABLE 422            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            323

TABLE 423            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                323

TABLE 424            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            324

TABLE 425            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            324

TABLE 426            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            325

TABLE 427            AUSTRALIA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            325

TABLE 428            SOUTH KOREA: CANCER INCIDENCE, MORTALITY AND PREVALENCE,

BY TYPE, 2022     326

TABLE 429            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            326

TABLE 430            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            327

TABLE 431            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            327

TABLE 432            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            327

TABLE 433            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            328

TABLE 434            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            328

TABLE 435            SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            329

TABLE 436            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            330

TABLE 437            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            330

TABLE 438            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            330

TABLE 439            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022–2029 (USD MILLION)                 331

TABLE 440            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            331

TABLE 441            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            332

TABLE 442            REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            332

TABLE 443            LATIN AMERICA: ESTIMATED NUMBER OF CANCER NEW CASES

FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]   333

TABLE 444          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            334

TABLE 445          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            334

TABLE 446          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            335

TABLE 447          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            335

TABLE 448          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            335

TABLE 449          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            336

TABLE 450          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            336

TABLE 451          LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            337

TABLE 452            BRAZIL: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022       338

TABLE 453            BRAZIL: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     338

TABLE 454            BRAZIL: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         339

TABLE 455            BRAZIL: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                339

TABLE 456            BRAZIL: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            339

TABLE 457            BRAZIL: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            340

TABLE 458            BRAZIL: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            340

TABLE 459            BRAZIL: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)                341

TABLE 460            MEXICO: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022             342

TABLE 461            MEXICO: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     342

TABLE 462            MEXICO: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022–2029 (USD MILLION)         342

TABLE 463            MEXICO: HUMAN ORGANOIDS MARKET, BY TYPE, 2022–2029 (USD MILLION)                343

TABLE 464            MEXICO: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            343

TABLE 465            MEXICO: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            343

TABLE 466            MEXICO: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            344

TABLE 467            MEXICO: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029 (USD MILLION)     344

TABLE 468            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            345

TABLE 469            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            345

TABLE 470            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            346

TABLE 471            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022–2029 (USD MILLION)                 346

TABLE 472            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            347

TABLE 473            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            347

TABLE 474            REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            348

TABLE 475            AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES

BETWEEN 0 TO 85+ OF AGE, 2022–2045   349

TABLE 476            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            349

TABLE 477            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            350

TABLE 478            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            350

TABLE 479            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022–2029 (USD MILLION)                 350

TABLE 480            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            351

TABLE 481            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            351

TABLE 482            MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            352

TABLE 483            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            353

TABLE 484            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY SOURCE,

2022–2029 (USD MILLION)            354

TABLE 485            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY TYPE,

2022–2029 (USD MILLION)            354

TABLE 486            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2022–2029 (USD MILLION)            354

TABLE 487            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,

2022–2029 (USD MILLION)            355

TABLE 488            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            355

TABLE 489            GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY END USER,

2022–2029 (USD MILLION)            356

TABLE 490            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN

HUMAN ORGANOIDS MARKET  357

TABLE 491            HUMAN ORGANOIDS MARKET: DEGREE OF COMPETITION 360

TABLE 492            HUMAN ORGANOIDS MARKET: REGION FOOTPRINT       363

TABLE 493            HUMAN ORGANOIDS MARKET: PRODUCT FOOTPRINT       364

TABLE 494            HUMAN ORGANOIDS MARKET: SOURCE FOOTPRINT       365

TABLE 495            HUMAN ORGANOIDS MARKET: APPLICATION FOOTPRINT       365

TABLE 496            HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS               367

TABLE 497            HUMAN ORGANOIDS MARKET: COMPETITIVE BENCHMARKING OF

STARTUP/SME PLAYERS               368

TABLE 498            HUMAN ORGANOIDS MARKET: PRODUCT LAUNCHES,

JANUARY 2021– AUGUST 2024      370

TABLE 499            HUMAN ORGANOIDS MARKET: DEALS, JANUARY 2021–AUGUST 2024       370

TABLE 500            THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW          372

TABLE 501            THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED             373

TABLE 502            THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES,

JANUARY 2021–AUGUST 2024       374

TABLE 503            THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021–AUGUST 2024           375

TABLE 504            CORNING INCORPORATED: COMPANY OVERVIEW          377

TABLE 505            CORNING INCORPORATED: PRODUCTS OFFERED             378

TABLE 506            CORNING INCORPORATED: DEALS, JANUARY 2021–AUGUST 2024           379

TABLE 507            MERCK: COMPANY OVERVIEW  381

TABLE 508            MERCK: PRODUCTS OFFERED   382

TABLE 509            MERCK: DEALS, JANUARY 2021–AUGUST 2024                 383

TABLE 510            MERCK: EXPANSIONS, JANUARY 2021–AUGUST 2024        383

TABLE 511            BIOIVT: COMPANY OVERVIEW  384

TABLE 512            BIOIVT: PRODUCTS OFFERED   384

TABLE 513            BIOIVT: DEALS, JANUARY 2021–AUGUST 2024                 388

TABLE 514            HUB ORGANOIDS: COMPANY OVERVIEW                 390

TABLE 515            HUB ORGANOIDS: PRODUCTS OFFERED                 390

TABLE 516            HUB ORGANOIDS: DEALS, JANUARY 2021–AUGUST 2024     390

TABLE 517            BICO: COMPANY OVERVIEW      392

TABLE 518            BICO: PRODUCTS OFFERED       393

TABLE 519            BICO: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024     394

TABLE 520            BICO: DEALS, JANUARY 2021–JUNE 2024 394

TABLE 521            BICO: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024     394

TABLE 522            BECYTES BIOTECHNOLOGIES: COMPANY OVERVIEW          395

TABLE 523            BECYTES BIOTECHNOLOGIES: PRODUCTS OFFERED             395

TABLE 524            INSPHERO: COMPANY OVERVIEW            396

TABLE 525            INSPHERO: PRODUCTS OFFERED             396

TABLE 526            INSPHERO: DEALS, JANUARY 2021–AUGUST 2024                 397

TABLE 527            GBA GROUP: COMPANY OVERVIEW        398

TABLE 528            GBA GROUP: PRODUCTS OFFERED         398

TABLE 529            GBA GROUP: DEALS, JANUARY 2021–AUGUST 2024        398

TABLE 530            KIRKSTALL: COMPANY OVERVIEW          399

TABLE 531            KIRKSTALL: PRODUCTS OFFERED           399

TABLE 532            MIMETAS: COMPANY OVERVIEW              400

TABLE 533            MIMETAS: PRODUCTS OFFERED               400

TABLE 534            MIMETAS: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024           401

TABLE 535            MIMETAS: DEALS, JANUARY 2021–AUGUST 2024                 401

TABLE 536            NEUROMICS: COMPANY OVERVIEW       402

TABLE 537            NEUROMICS: PRODUCTS OFFERED        402

TABLE 538            PRIMACYT CELL CULTURE TECHNOLOGY GMBH: COMPANY OVERVIEW    404

TABLE 539            PRIMACYT CELL CULTURE TECHNOLOGY GMBH: PRODUCTS OFFERED     404

TABLE 540            STEMCELL TECHNOLOGIES: COMPANY OVERVIEW          405

TABLE 541            STEMCELL TECHNOLOGIES: PRODUCTS OFFERED             405

TABLE 542            STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021–AUGUST 2024           406

TABLE 543            STEMCELL TECHNOLOGIES: EXPANSIONS, JANUARY 2021–AUGUST 2024       406

LIST OF FIGURES

FIGURE 1              HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY             43

FIGURE 2              BREAKDOWN OF PRIMARY INTERVIEWS:

SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS             48

FIGURE 3              BREAKDOWN OF PRIMARY INTERVIEWS:

BY COMPANY TYPE, DESIGNATION, AND REGION            49

FIGURE 4              BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH              50

FIGURE 5              CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS                 51

FIGURE 6              HUMAN ORGANOIDS MARKET: TOP-DOWN APPROACH         52

FIGURE 7              DATA TRIANGULATION METHODOLOGY                 53

FIGURE 8              HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)      56

FIGURE 9              HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)                57

FIGURE 10           HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)       57

FIGURE 11            HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,

2024 VS. 2029 (USD MILLION)      58

FIGURE 12            HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2024 VS. 2029 (USD MILLION)         59

FIGURE 13            HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)       60

FIGURE 14            HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)      61

FIGURE 15            HUMAN ORGANOIDS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)                61

FIGURE 16            GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR

ANIMAL TESTING MODELS TO DRIVE MARKET GROWTH                 63

FIGURE 17            LIVER MODELS TO DOMINATE MARKET TILL 2029        63

FIGURE 18            ADULT STEM CELLS SEGMENT TO HOLD LARGEST SHARE TILL 2029           64

FIGURE 19            READY-TO-USE PRODUCTS SEGMENT TO RETAIN MARKET LEADERSHIP  64

FIGURE 20            DEVELOPMENTAL BIOLOGY AND DRUG TOXICITY & EFFICACY TESTING TO COMMAND LARGEST SHARES 65

FIGURE 21            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO

DOMINATE MARKET IN 2029       65

FIGURE 22            ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD           66

FIGURE 23            HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          67

FIGURE 24            NUMBER OF CLINICAL TRIALS, BY COUNTRY, 2022        73

FIGURE 25            NUMBER OF ARTICLES RELATED TO HUMAN ORGANOIDS, 2018–2023 73

FIGURE 26            US: NUMBER OF ORGAN TRANSPLANTS (2024)                 74

FIGURE 27            AVERAGE SELLING PRICE OF FRESH CELLS (2024)    78

FIGURE 28            PATENT ANALYSIS FOR HUMAN ORGANOIDS (JANUARY 2014–DECEMBER 2023)              79

FIGURE 29            VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING

AND ASSEMBLY PHASES                81

FIGURE 30            HUMAN ORGANOIDS MARKET: SUPPLY CHAIN ANALYSIS            82

FIGURE 31            HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS            85

FIGURE 32            HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS           86

FIGURE 33            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS          88

FIGURE 34            KEY BUYING CRITERIA FOR HUMAN ORGANOIDS      89

FIGURE 35            HUMAN ORGANOIDS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS         97

FIGURE 36            HUMAN ORGANOIDS MARKET: DEALS AND FUNDING            98

FIGURE 37            MARKET POTENTIAL OF AI TO ENHANCE RESEARCH AND DEVELOPMENT IN HUMAN ORGANOIDS MARKET               100

FIGURE 38            NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT       265

FIGURE 39            ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT          306

FIGURE 40            REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET

(2021–2023)          359

FIGURE 41            MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2023)     360

FIGURE 42            HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023       362

FIGURE 43            HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT       363

FIGURE 44            HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2023                367

FIGURE 45            EV/EBITDA OF KEY VENDORS   368

FIGURE 46            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            368

FIGURE 47            HUMAN ORGANOIDS MARKET: BRAND COMPARISON FOR HEPATOCYTES          369

FIGURE 48            THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT          373

FIGURE 49            CORNING INCORPORATED: COMPANY SNAPSHOT          378

FIGURE 50            MERCK: COMPANY SNAPSHOT  382

FIGURE 51            BICO: COMPANY SNAPSHOT      393

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧